Epidemiology and Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.
University of Bordeaux, Centre INSERM U1219, France.
Clin Infect Dis. 2016 May 1;62(9):1161-1168. doi: 10.1093/cid/ciw036. Epub 2016 Feb 7.
The diagnosis of tuberculosis in human immunodeficiency virus (HIV)-infected children is challenging. We assessed the performance of alternative specimen collection methods for tuberculosis diagnosis in HIV-infected children using Xpert MTB/RIF (Xpert).
HIV-infected children aged ≤13 years with suspected intrathoracic tuberculosis were enrolled in 8 hospitals in Burkina Faso, Cambodia, Cameroon, and Vietnam. Gastric aspirates were taken for children aged <10 years and expectorated sputum samples were taken for children aged ≥10 years (standard samples); nasopharyngeal aspirate and stool were taken for all children, and a string test was performed if the child was aged ≥4 years (alternative samples). All samples were tested with Xpert. The diagnostic accuracy of Xpert for culture-confirmed tuberculosis was analyzed in intention-to-diagnose and per-protocol approaches.
Of 281 children enrolled, 272 (96.8%) had ≥1 specimen tested with Xpert (intention-to-diagnose population), and 179 (63.5%) had all samples tested with Xpert (per-protocol population). Tuberculosis was culture-confirmed in 29/272 (10.7%) children. Intention-to-diagnose sensitivities of Xpert performed on all, standard, and alternative samples were 79.3% (95% confidence interval [CI], 60.3-92.0), 72.4% (95% CI, 52.8-87.3), and 75.9% (95% CI, 56.5-89.7), respectively. Specificities were ≥97.5%. Xpert combined on nasopharyngeal aspirate and stool had intention-to-diagnose and per-protocol sensitivities of 75.9% (95% CI, 56.5-89.7) and 75.0% (95% CI, 47.6-92.7), respectively.
The combination of nasopharyngeal aspirate and stool sample is a promising alternative to methods usually recommended by national programs. Xpert performed on respiratory and stools samples enables rapid confirmation of tuberculosis diagnosis in HIV-infected children.
The ANRS (Agence Nationale de Recherche sur le Sida) 12229 PAANTHER (Pediatric Asian African Network for Tuberculosis and HIV Research) 01 study is registered at ClinicalTrials.gov (NCT01331811).
在人类免疫缺陷病毒(HIV)感染儿童中,结核病的诊断具有挑战性。我们评估了使用 Xpert MTB/RIF(Xpert)检测替代标本采集方法对 HIV 感染儿童进行结核病诊断的性能。
在布基纳法索、柬埔寨、喀麦隆和越南的 8 家医院招募了年龄≤13 岁且疑似患有胸内结核的 HIV 感染儿童。10 岁以下的儿童采集胃抽吸物,10 岁及以上的儿童采集咳痰样本(标准样本);所有儿童采集鼻咽抽吸物和粪便样本,如果儿童年龄≥4 岁,则采集 strings 测试(替代样本)。所有样本均用 Xpert 检测。采用意向诊断和方案设计方法分析 Xpert 对培养确诊结核病的诊断准确性。
在 281 名入组的儿童中,有 272 名(96.8%)至少有 1 份标本用 Xpert 检测(意向诊断人群),有 179 名(63.5%)用 Xpert 检测了所有样本(方案设计人群)。272 名儿童中,29 名(10.7%)经培养确诊为结核病。Xpert 对所有、标准和替代样本的意向诊断灵敏度分别为 79.3%(95%置信区间 [CI],60.3-92.0)、72.4%(95% CI,52.8-87.3)和 75.9%(95% CI,56.5-89.7)。特异性均≥97.5%。鼻咽抽吸物和粪便样本联合 Xpert 的意向诊断和方案设计灵敏度分别为 75.9%(95% CI,56.5-89.7)和 75.0%(95% CI,47.6-92.7)。
鼻咽抽吸物和粪便样本的联合是国家方案通常推荐的方法的一种有前途的替代方法。Xpert 检测呼吸道和粪便样本能够快速确认 HIV 感染儿童的结核病诊断。
ANRS(艾滋病国家研究署)12229 项 PAANTHER(亚洲非洲儿童结核病和 HIV 研究网络)01 研究在 ClinicalTrials.gov 注册(NCT01331811)。